enzymes – Page 3 – Dermatol Sinica

Predicting T Cell Receptor Antigen Specificity From Structural Features Derived From Homology Models of Receptor-Peptide-Major Histocompatibility ComplexesPredicting T Cell Receptor Antigen Specificity From Structural Features Derived From Homology Models of Receptor-Peptide-Major Histocompatibility Complexes

| Hunter | 0 Comment

The physical interaction between the T cell receptor (TCR) and its cognate antigen causes T cells to activate and participate in the immune response. Understanding this physical interaction is important

CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cellsCXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

| Hunter | 0 Comment

The efficacy of chimeric antigen receptor (CAR) T continues to be not optimum for stable tumors, partly because of the lack of T cell infiltration to the tumor website. One

Interferon-gamma: an overview of signals, mechanisms and functions.Interferon-gamma: an overview of signals, mechanisms and functions.

| Hunter | 0 Comment

Interferon-gamma: an overview of signals, mechanisms and functions. Interferon-gamma (IFN-gamma) coordinates a diverse array of cellular programs through transcriptional regulation of immunologically relevant genes. This article reviews the current understanding

Type III protein secretion systems in bacterial pathogens of animals and plants.Type III protein secretion systems in bacterial pathogens of animals and plants.

| Hunter | 0 Comment

Type III protein secretion systems in bacterial pathogens of animals and plants. Various gram-negative animal and plant pathogens use a novel, sec-independent protein secretion system as a basic virulence mechanism. It is becoming increasingly

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

| Hunter | 0 Comment

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Antiviral immunity against a pathogen is mounted upon recognition by the host of virally associated structures. One